Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines

作者: Luis Martinez-Sobrido , Juan Carlos de la Torre

DOI: 10.1080/14760584.2016.1182024

关键词: BiodefenseVirologyArenavirusRibavirinViral hemorrhagic feverViral vectorAttenuated vaccineImmunologyLassa virusBiologyViral Vaccine

摘要: ABSTRACTIntroduction: Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) disease in humans and pose significant public health problems their endemic regions. Moreover, HF arenaviruses represent credible biodefense threats. There are not FDA-approved arenavirus vaccines current anti-arenaviral therapy is limited to an off-label use of ribavirin that only partially effective.Areas covered: Live-attenuated (LAV) the most feasible approach control within Different platforms, including recombinant viral vectors expressing LASV antigens, attenuated reassortant have been used develop LAV candidates against with promising results animal models infection, but none them has entered a clinical trial. These vaccine efforts subject recent reviews will be examined this review, which focused on new avenues for development safe effe...

参考文章(66)
McCormick Jb, Weissenbacher Mc, Rodríguez M, Antiviral effect of ribavirin on Junin virus replication in vitro. Revista Argentina De Microbiologia. ,vol. 18, pp. 69- 74 ,(1986)
C. J. Peters, Human infection with arenaviruses in the Americas. Current Topics in Microbiology and Immunology. ,vol. 262, pp. 65- 74 ,(2002) , 10.1007/978-3-642-56029-3_3
J. Casals, T. P. Monath, Diagnosis of Lassa Fever and the Isolation and Management of Patients Bulletin of The World Health Organization. ,vol. 52, pp. 707- 715 ,(1975)
David Walker, J. V. Lange, H. Wulff, F. A. Murphy, Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis Bulletin of The World Health Organization. ,vol. 52, pp. 523- 534 ,(1975)
Freedman Do, Woodall J, Emerging infectious diseases and risk to the traveler. Medical Clinics of North America. ,vol. 83, pp. 865- 883 ,(1999)
Elsa B Damonte, Celia E Coto, Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Advances in Virus Research. ,vol. 58, pp. 125- 155 ,(2002) , 10.1016/S0065-3527(02)58004-0
KristianáG Andersen, B áJesse Shapiro, ChristianáB Matranga, Rachel Sealfon, AaronáE Lin, LinaáM Moses, OnikepeáA Folarin, Augustine Goba, Ikponmwonsa Odia, PhilomenaáE Ehiane, Mambu Momoh, EleinaáM England, Sarah Winnicki, LuisáM Branco, StephenáK Gire, Eric Phelan, Ridhi Tariyal, Ryan Tewhey, Omowunmi Omoniwa, Mohammed Fullah, Richard Fonnie, Mbalu Fonnie, Lansana Kanneh, Simbirie Jalloh, Michael Gbakie, Sidiki Saffa, Kandeh Karbo, AdrianneáD Gladden, James Qu, Matthew Stremlau, Mahan Nekoui, HilaryáK Finucane, Shervin Tabrizi, JosepháJ Vitti, Bruce Birren, Michael Fitzgerald, Caryn McCowan, Andrea Ireland, AaronáM Berlin, James Bochicchio, Barbara Tazon-Vega, NialláJ Lennon, ElizabetháM Ryan, Zach Bjornson, DannyáA Milner Jr, AmandaáK Lukens, Nisha Broodie, Megan Rowland, Megan Heinrich, Marjan Akdag, JohnáS Schieffelin, Danielle Levy, Henry Akpan, DanieláG Bausch, Kathleen Rubins, JosepháB McCormick, EricáS Lander, Stephan GŘnther, Lisa Hensley, Sylvanus Okogbenin, StephenáF Schaffner, PeteráO Okokhere, S áHumarr Khan, DonaldáS Grant, GeorgeáO Akpede, DannyáA Asogun, Andreas Gnirke, JoshuaáZ Levin, ChristianáT Happi, RobertáF Garry, PardisáC Sabeti, Viral Hemorrhagic Fever Consortium, None, Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus Cell. ,vol. 162, pp. 738- 750 ,(2015) , 10.1016/J.CELL.2015.07.020
Jingpeng Gao, Chunchun Meng, Zongyan Chen, Chuanfeng Li, Guangqing Liu, Codon optimization of the rabbit hemorrhagic disease virus (RHDV) capsid gene leads to increased gene expression in Spodoptera frugiperda 9 (Sf9) cells. Journal of Veterinary Science. ,vol. 14, pp. 441- 447 ,(2013) , 10.4142/JVS.2013.14.4.441
Brian B. Gowen, Michael R. Holbrook, Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Research. ,vol. 78, pp. 79- 90 ,(2008) , 10.1016/J.ANTIVIRAL.2007.10.002